Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 3, 2006, Pages 345-351

  van der Graaf, Anouk ^a   Hutten, Barbara A ^a   Kastelein, John J P ^a   Vissers, Maud N ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Familial hypercholesterolemia; Low density lipoprotein; Statins; Women

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; PLACEBO; RESIN; STANOL ESTER;

AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; HETEROZYGOSITY; HUMAN; INCIDENCE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT PLANNING;

ADULT; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 33744462063     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.3.345     Document Type: Review

References (57)

1. Goldstein JL, Hobbs HH, Brown HS. The Metabolic Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.). McGraw-Hill, NY, USA. 2863-2913 (2001).
2. Vohl MC, Moorjani S, Roy M et al. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the province of Quebec. Clin. Genet. 52, 1-6 (1997).
3. de Jongh S, Lilien MR, Bakker HD et al. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 163, 193-197 (2002).
4. Wiegman A, Groot E, Hutten BA et al. Arterial intima-media thickness i n children heterozygous for familial hypercholesterolemia. Lancet 363, 369-370 (2004).
5. Jansen AC, van WS, Defesche JC, Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Curr. Opin. Lipidol. 13, 165-171 (2002).
6. Koeijvoets KC, Rodenburg J, Hutten BA et al. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 112, 3168-3173 (2005).
7. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 106, 3031-3036 (2002).
8. Gaudet D, Vohl MC, Couture P et al. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. Atherosclerosis 143, 153-161 (1999).
9. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2, 1380-1382 (1969).
10. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 142, 105-112 (1999).
11. Beaumont V, Jacotot B, Beaumont JL. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. Atherosclerosis 24, 441-450 (1976).
12. Gagne C, Moorjani S, Brun D, Toussaint M, Lupien PJ. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis 34, 13-24 (1979).
13. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 11, 290-297 (1991).
14. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br. Med. J. 303, 893-896 (1991).
15. Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256, 482-490 (2004).
16. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583-1587 (2005).
17. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340, 1801-1811 (1999).
18. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 10, 615-624 (1996).
19. Arnal JF, Bayard F. Vasculoprotective effects of oestrogens. Clin. Exp. Pharmacol. Physiol. 28, 1032-1034 (2001).
20. Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Clinical review 91: female sex hormones and cardiovascular disease in women. J. Clin. Endocrinol. Metab. 82, 3913-3918 (1997).
21. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98, 83-90 (1993).
22. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 12, 321-331 (1990).
23. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
24. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 113, 5-14 (2006).
25. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 288, 872-881 (2002).
26. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100, 1481-1492 (1999).
27. Yagi K, Hifumi S, Nohara A et al. Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. Circ. J. 68, 623-627 (2004).
28. Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. Arteriosclerosis 8, 163-167 (1988).
29. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 49, 476-488 (1974).
30. Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N. Engl. J. Med. 353, 1252-1260 (2005).
31. Ellison RC, Zhang Y, Qureshi MM et al. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am. Heart J. 147, 529-535 (2004).
32. de Sauvage Nolting PR, Defesche JC, Buirma RJ et al. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J. Intern. Med. 253, 161-168 (2003).
33. Hopkins PN, Stephenson S, Wu LL et al. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 87, 547-553 (2001).
34. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
35. Hopkins PN. Familial hypercholesterolemia-improving treatment and meeting guidelines. Int. J. Cardiol. 89, 13-23 (2003).
36. Connor WE, Connor SL. Importance of diet in the treatment of familial hypercholesterolemia. Am. J. Cardiol. 72, 42D-53D (1993).
37. Law M. Plant sterol and stanol margarines and health. Br. Med. J. 320, 861-864 (2000).
38. Katan MB, Grundy SM, Jones P et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin. Proc. 78, 965-978 (2003).
39. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
40. Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am. J. Cardiol. 96, 47D-50D (2005).
41. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55-68 (2004).
42. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
43. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168, 1-14 (2003).
44. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 142, 105-112 (1999).
45. Betteridge DJ, Bhatnager D, Bing RF et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. Br. Med. J. 304, 1335-1338 (1992).
46. de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am. J. Cardiol. 90, 181-184 (2002).
47. Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577-581 (2001).
48. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 92, 1287-1293 (2003).
49. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 20(251), 351-364 (1984).
50. Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159, 1893-1900 (1999).
51. Rodenburg J, Vissers MN, Daniels SR, Wiegman A, Kastelein. Lipid-lowering Medications. Pediatr. Endocrinol. Rev. 2, 109-119 (2006).
52. Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. 90, 1092-1097 (2002).
53. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol 90, 1084-1091 (2002).
54. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291, 2243-2252 (2004).
55. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292, 331-337 (2004).
56. Greene O, Durrington P. Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK. J. R. Soc. Med. 97, 226-229 (2004).
57. Bhargava R, Sandhu G, Armstrong M et al. Gender bias in the use of lipid-lowering therapy. Circulation (Suppl.) 112, 11-817 (2006).